this post was submitted on 02 Apr 2024
71 points (91.8% liked)

Piracy: ꜱᴀɪʟ ᴛʜᴇ ʜɪɢʜ ꜱᴇᴀꜱ

54539 readers
203 users here now

⚓ Dedicated to the discussion of digital piracy, including ethical problems and legal advancements.

Rules • Full Version

1. Posts must be related to the discussion of digital piracy

2. Don't request invites, trade, sell, or self-promote

3. Don't request or link to specific pirated titles, including DMs

4. Don't submit low-quality posts, be entitled, or harass others



Loot, Pillage, & Plunder

📜 c/Piracy Wiki (Community Edition):


💰 Please help cover server costs.

Ko-Fi Liberapay
Ko-fi Liberapay

founded 1 year ago
MODERATORS
 

cross-posted from: https://mander.xyz/post/11304633

Ozempic maker Novo Nordisk facing pressure as study finds $1,000 appetite suppressant can be made for just $5

all 20 comments
sorted by: hot top controversial new old
[–] [email protected] 13 points 7 months ago

Ever since Ozempic became more profitable to sell to fat people looking for an easy weight loss hack rather than the diabetics who actually needed it, we've seen nothing but bullshit attributed to the drug.

[–] [email protected] -1 points 7 months ago (2 children)

I read the article and I don't think it factors in the upfront cost of R&D, Compliance, etc, so that's basically a fantasy number.

[–] [email protected] 3 points 7 months ago

Those are the costs of doing business, and can be greatly exaggerated. And other counties produce profitable drugs even with price restrictions. We're so accustomed to price gouging, that we don't recognize it.

[–] [email protected] 3 points 7 months ago* (last edited 7 months ago)

You're probably right. It's more than likely the cost per dose. Which is also what the $1000 figure represents.

The Vermont independent (Bernie) called on Novo Nordisk to lower the list price of Ozempic to $155 a month or less, in line with what it charges in other countries.

Somehow they can justify selling it for $155 a dose (per month?) in other countries while still making a profit above the overhead and compliance costs.